Bassan J Allan1, Bo Wang1, James S Davis1, Punam P Parikh1, Eduardo A Perez1, Holly L Neville1, Juan E Sola2. 1. Department of Surgery, Division of Pediatric Surgery, DeWitt-Daughtry Family, University of Miami Miller School of Medicine, Miami, FL 33136, USA. 2. Department of Surgery, Division of Pediatric Surgery, DeWitt-Daughtry Family, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Electronic address: jsola@med.miami.edu.
Abstract
PURPOSE: This study evaluates the incidence trends and clinical outcomes of children with hepatocellular carcinoma (HCC) and assesses factors predictive of patient survival. METHODS: The Surveillance, Epidemiology, and End Results registry was queried from 1973 to 2009 for all patients between ages 0 and 19 with primary HCC. Demographics, tumor histology, surgical intervention, and patient survival were collected. RESULTS: Overall, 218 patients were identified. The annual age-adjusted incidence was 0.05 cases per 100,000 in 2009. Fibrolamellar subtype tumors were exclusive to children >5years old and exhibited greater survival compared to non-fibrolamellar subtype (57% vs. 28%, respectively, p=0.002). Tumor extirpation for patients with resectable disease significantly improved overall survival at 5years compared to no surgery (60% vs. 0%, respectively, p<0.0001). Overall 5-, 10- and 20-year survival for the entire cohort was 24%, 23%, and 8%, respectively. Independent prognostic factors of lower mortality according to multivariate analysis were surgical resection (hazard ratio (HR)=0.18), non-Hispanic ethnicity (HR=0.52), and local disease at presentation (HR=0.46). CONCLUSION: Over the past four decades, the incidence of HCC has remained relatively stable. Children of Hispanic ethnicity have high mortality rates. However, HCC resection for curative intent significantly improves outcomes.
PURPOSE: This study evaluates the incidence trends and clinical outcomes of children with hepatocellular carcinoma (HCC) and assesses factors predictive of patient survival. METHODS: The Surveillance, Epidemiology, and End Results registry was queried from 1973 to 2009 for all patients between ages 0 and 19 with primary HCC. Demographics, tumor histology, surgical intervention, and patient survival were collected. RESULTS: Overall, 218 patients were identified. The annual age-adjusted incidence was 0.05 cases per 100,000 in 2009. Fibrolamellar subtype tumors were exclusive to children >5years old and exhibited greater survival compared to non-fibrolamellar subtype (57% vs. 28%, respectively, p=0.002). Tumor extirpation for patients with resectable disease significantly improved overall survival at 5years compared to no surgery (60% vs. 0%, respectively, p<0.0001). Overall 5-, 10- and 20-year survival for the entire cohort was 24%, 23%, and 8%, respectively. Independent prognostic factors of lower mortality according to multivariate analysis were surgical resection (hazard ratio (HR)=0.18), non-Hispanic ethnicity (HR=0.52), and local disease at presentation (HR=0.46). CONCLUSION: Over the past four decades, the incidence of HCC has remained relatively stable. Children of Hispanic ethnicity have high mortality rates. However, HCC resection for curative intent significantly improves outcomes.
Authors: Matthew P Lungren; Alexander J Towbin; Derek J Roebuck; Eric J Monroe; Anne E Gill; Avnesh Thakor; Richard B Towbin; Anne Marie Cahill; C Matthew Hawkins Journal: Pediatr Radiol Date: 2018-01-23
Authors: Samuel Golpanian; Eduardo A Perez; Jun Tashiro; John I Lew; Juan E Sola; Anthony R Hogan Journal: Pediatr Surg Int Date: 2015-12-30 Impact factor: 1.827
Authors: Elise Kang; Mercedes Martinez; Hanna Moisander-Joyce; Yvonne M Saenger; Adam D Griesemer; Tomoaki Kato; Darrell J Yamashiro; Helen Remotti; Robyn D Gartrell Journal: Pediatr Transplant Date: 2021-12-15
Authors: Scott S Short; Zachary J Kastenberg; Guo Wei; Alex Bondoc; Roshni Dasgupta; Greg M Tiao; Erin Watters; Todd E Heaton; Dimitra Lotakis; Michael P La Quaglia; Andrew J Murphy; Andrew M Davidoff; Sara A Mansfield; Max R Langham; Timothy B Lautz; Riccardo A Superina; Katherine C Ott; Marcus M Malek; Katrina M Morgan; Eugene S Kim; Abigail Zamora; Danny Lascano; Jonathan Roach; Joseph T Murphy; David H Rothstein; Sanjeev A Vasudevan; Richard Whitlock; Dave R Lal; Brian Hallis; Andreana Bütter; Reto M Baertschiger; Eveline Lapidus-Krol; Juan Putra; Elisabeth R Tracy; Jennifer H Aldrink; Jordan Apfeld; Hau D Le; Keon Y Park; Barrie S Rich; Richard D Glick; Elizabeth A Fialkowski; Alan F Utria; Rebecka L Meyers; Kimberly J Riehle Journal: Cancer Date: 2022-05-13 Impact factor: 6.921
Authors: Roberta Angelico; Chiara Grimaldi; Maria Cristina Saffioti; Aurora Castellano; Marco Spada Journal: Transl Gastroenterol Hepatol Date: 2018-09-10
Authors: Jorge L Rodriguez-Gil; Simona E Bianconi; Nicole Farhat; David E Kleiner; Marie Nelson; Forbes D Porter Journal: Am J Med Genet A Date: 2021-06-17 Impact factor: 2.578